CERB2 (Her2/neu) IHC

This test detects the presence of Her2/neu protein in breast tissue samples. This is important information as overexpression of HER2 is indicative of a specific subtype of breast cancer that may respond well to targeted therapies like Herceptin.

• The primary purpose of the CERB2 (Her 2/neu) IHC test is to identify breast cancer patients whose tumors exhibit HER2 overexpression.
• To assess the aggressiveness of breast cancer and predict its prognosis.
• To guide treatment decisions by identifying patients who may benefit from targeted therapy. It helps in determining the most appropriate therapeutic approach, particularly for the use of drugs like Herceptin (Trastuzumab), which specifically targets HER2-positive cancer cells.
• To monitor the response to treatment and evaluate its effectiveness.

• Patients diagnosed with breast cancer to determine the appropriate treatment plan
• The test is typically recommended for patients with early-stage breast cancer as well as metastatic breast cancer
• Patients with aggressive forms of breast cancer to assess the prognosis and guide treatment decisions
• Patients undergoing targeted therapy with Herceptin to monitor their response to treatment
• Patients with a family history of breast cancer or genetic risk factors

If the CERB2 (Her 2/neu) IHC test results indicate abnormal levels of HER2 expression, it suggests that the patient's breast cancer is HER2-positive. In such cases, targeted therapies such as Herceptin may be recommended as part of the treatment plan to specifically target and inhibit the HER2-positive cancer cells.

During this test:

• A small tissue sample will be collected from the affected area.
• The sample will be sent to the laboratory for analysis.
• Special staining techniques will be used to identify and measure the presence of Her2/neu protein.
• The results will be reported to your doctor for further discussion and interpretation.

Before the test:

• Ensure that you provide the original histopathology report and all relevant clinical and radiological details
• Follow any specific instructions provided by your doctor regarding fasting or medication restrictions
• Be prepared to share your medical history and any ongoing treatments or medications

• Estrogen receptor (ER) and progesterone receptor (PR) testing: Determines hormone receptor status that affects treatment decisions
• Ki-67 testing: Measures the level of a protein called Ki-67, which indicates the rate of cell division and helps predict the tumour's growth potential
• HER2 gene amplification testing: Determines the number of copies of the HER2 gene, which further confirms Her2/neu protein overexpression

• Her2/neu immunohistochemistry
• Her2/neu IHC
• CERB2 IHC Test